Bevacizumab is a recombinant human monoclonal antibody that selectively neutralizes VEGF, which showed improved progression-free survival (PFS) and objective response rates, leading to the US Food and Drug Administration approval for recurrent GBM in 20094,5. The gene discussed is VEGFA; the disease is glioblastoma.